Metreleptin for Generalized Lipodystrophy
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines how metreleptin, a medication, works for people with generalized lipodystrophy. Generalized lipodystrophy prevents the body from properly storing fat, causing various health issues. The trial aims to determine if the body creates antibodies against metreleptin and to ensure its safety for new users. It targets individuals with a confirmed diagnosis of this condition who have not previously tried metreleptin. Participants should not have received metreleptin treatment before and should not be involved in other studies. As a Phase 4 trial, metreleptin has already received FDA approval and proven effective; this research seeks to understand how it benefits more patients.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor to get a clear answer.
What is the safety track record for metreleptin?
Research has shown that metreleptin, approved by the FDA for treating leptin deficiency in generalized lipodystrophy, has undergone safety studies. In one study, 48 patients with this condition were monitored. Common side effects included low blood sugar in 13% of patients and injection site reactions, such as redness and hives, in 4% of patients. While these side effects are important to note, most participants did not experience them.
Given its approval and existing safety data, metreleptin is generally well-tolerated for its approved use. However, this study aims to further explore any risks related to the development of antibodies against metreleptin.12345Why are researchers enthusiastic about this study treatment?
Metreleptin is unique because it directly addresses leptin deficiency, which is a core issue in generalized lipodystrophy. Unlike other treatments that manage symptoms indirectly, metreleptin acts as a recombinant form of human leptin, effectively replacing the missing hormone. This approach not only targets the root cause of the metabolic problems associated with lipodystrophy but also offers a more tailored treatment option that can improve both metabolic control and quality of life for patients. Researchers are excited about metreleptin because it represents a more precise and potentially more effective way to manage this challenging condition compared to existing options.
What is the effectiveness track record for metreleptin in treating generalized lipodystrophy?
Research shows that metreleptin, the treatment under study in this trial, helps address metabolic problems in people with generalized lipodystrophy. Studies have found that it reduces food intake and improves insulin use, which is crucial for controlling blood sugar levels. One study found that metreleptin can increase both lifespan and quality of life. It is already approved to treat issues from leptin deficiency in these patients, indicating strong evidence of its effectiveness for this condition.678910
Who Is on the Research Team?
Janet Boylan
Principal Investigator
Aegerion Pharmaceuticals, Inc.
Are You a Good Fit for This Trial?
This trial is for individuals over 1 year old with congenital or acquired generalized lipodystrophy who are starting MYALEPT treatment. Participants need to consent, use contraception if of childbearing potential, and not have used metreleptin before. They shouldn't be at high risk as per the investigator's opinion, have a recent history of substance abuse, HIV positive status, or severe reactions to metreleptin.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily SC metreleptin treatment to assess immunogenicity and potential antibody development
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Metreleptin
Trial Overview
The study tests the immune response to Metreleptin in patients with generalized lipodystrophy. It's an open-label Phase 4 trial assessing risks associated with developing antibodies against Metreleptin following its market approval.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Subjects will receive prescribed dosage of metreleptin as indicated in the USPI Patients (males and females) ≤ 40 kg: 0.06mg/kg Male patients \> 40 kg: 2.5mg Female patients \> 40 kg: 5mg
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aegerion Pharmaceuticals, Inc.
Lead Sponsor
Citations
Effects of Metreleptin on Patient Outcomes and Quality of Life ...
Quality-adjusted life-year gains associated with 12 months of treatment with metreleptin were estimated at 0.313 for generalized and 0.117 for partial ...
Efficacy | Myalept® (metreleptin) for injection | HCP
Effects of Metreleptin on patient outcomes and quality of life in generalized and partial lipodystrophy. J Endocrin Soc. 2021;5(4):1-16. IMPORTANT SAFETY ...
Effects of Metreleptin in Patients With Generalized ...
Metreleptin was shown to be effective in causing sustained improvement in metabolic abnormalities in patients with generalized lipodystrophy (4-6). However, ...
NCT02262832 | Compassionate Use of Metreleptin in ...
This study showed that metreleptin ameliorates metabolic and endocrine abnormalities in lipodystrophy, including reducing food intake, improving insulin ...
Pharmacoeconomic Review - Metreleptin (Myalepta) - NCBI
In the CADTH base case, metreleptin plus supportive care was associated with an incremental cost-effectiveness ratio (ICER) of $5,308,188 per QALY gained ...
Safety | Myalept® (metreleptin) for injection | HCP
Six patients (13%) had 7 adverse reactions of hypoglycemia. · Two patients (4%) with generalized lipodystrophy reported injection-site erythema and urticaria.
The Metreleptin Effectiveness and Safety Registry (MEASuRE)
One approach to address the paucity of information regarding rare diseases, including lipodystrophy, is to use patient registries—organized ...
MYALEPT Label - accessdata.fda.gov
The safety of MYALEPT was evaluated in 48 patients with generalized lipodystrophy in a single-arm, open-label study [see Clinical Studies (14.1)]. The median ...
Metreleptin (Myalept) - Medical Clinical Policy Bulletins
The safety and effectiveness of Myalept were evaluated in an open-label, single-arm study that included 48 patients with congenital or acquired generalized ...
Metreleptin Effectiveness and Safety Registry
People with GL have a lack of fatty tissue. Myalept is a drug that is approved by the Food and Drug Administration (FDA) to treat GL. It is also called ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.